91 related articles for article (PubMed ID: 23547855)
1. Frequency of hospitalizations prior to and after conversion to a rebate pharmaceutical in depression patients in Germany.
Kostev K; May U; Ott C; Paul M; Schetschok K; Tingelhoff M; Claus C; Waehlert L
Int J Clin Pharmacol Ther; 2013 May; 51(5):416-22. PubMed ID: 23547855
[TBL] [Abstract][Full Text] [Related]
2. The negative impact of rebate contracts on the health care of patients with depression in Germany.
Kostev K; Fuchs S; Bauer C; May U
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):397-402. PubMed ID: 21612747
[TBL] [Abstract][Full Text] [Related]
3. Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany.
Kostev K; May U; Hog D; Eisel J; Kremmers T; Kosteic M; Waehlert L; Hadji P
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):969-75. PubMed ID: 24120719
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
5. Substitution of theophylline slow-release formulations according to the rebate contracts in the German statutory health insurance.
Weissenfeld J; Lüngen M; Stock S; Drabik A; Gerber A
Arzneimittelforschung; 2009; 59(9):476-81. PubMed ID: 19856796
[TBL] [Abstract][Full Text] [Related]
6. Correlation of antidepressive agents and the mortality of end-stage renal disease.
Tsai CJ; Loh el-W; Lin CH; Yu TM; Chan CH; Lan TH
Nephrology (Carlton); 2012 May; 17(4):390-7. PubMed ID: 22260522
[TBL] [Abstract][Full Text] [Related]
7. The cost of hospitalization in Crohn's disease.
Cohen RD; Larson LR; Roth JM; Becker RV; Mummert LL
Am J Gastroenterol; 2000 Feb; 95(2):524-30. PubMed ID: 10685762
[TBL] [Abstract][Full Text] [Related]
8. [Regional differences in the use of 'no substitution' in the elderly after introduction of rebate contracts].
Hoffmann F; Windt R; Glaeske G
Gesundheitswesen; 2011 Jul; 73(7):438-42. PubMed ID: 20544592
[TBL] [Abstract][Full Text] [Related]
9. Direct costs associated with depressive symptoms in late life: a 4.5-year prospective study.
Luppa M; König HH; Heider D; Leicht H; Motzek T; Schomerus G; Riedel-Heller SG
Int Psychogeriatr; 2013 Feb; 25(2):292-302. PubMed ID: 23083505
[TBL] [Abstract][Full Text] [Related]
10. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
[TBL] [Abstract][Full Text] [Related]
11. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
McCombs JS; Ahn J; Tencer T; Shi L
J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
[TBL] [Abstract][Full Text] [Related]
12. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
13. [Implementation of "aut idem" before and after introduction of rebate contracts].
Hoffmann F; Windt R; Glaeske G
Dtsch Med Wochenschr; 2010 Apr; 135(15):739-44. PubMed ID: 20373270
[TBL] [Abstract][Full Text] [Related]
14. The costs of atrial fibrillation in patients with cardiovascular comorbidities--a longitudinal analysis of German health insurance data.
Reinhold T; Lindig C; Willich SN; Brüggenjürgen B
Europace; 2011 Sep; 13(9):1275-80. PubMed ID: 21515590
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic issues in the treatment of depression.
Saklad SR
Pharmacotherapy; 1995; 15(6 Pt 2):76S-83S. PubMed ID: 8587854
[TBL] [Abstract][Full Text] [Related]
16. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
17. Increased antidepressant drug exposure in psoriasis patients: a longitudinal population-based cohort study.
Dowlatshahi EA; Wakkee M; Herings RM; Hollestein LM; Nijsten T
Acta Derm Venereol; 2013 Sep; 93(5):544-50. PubMed ID: 23529077
[TBL] [Abstract][Full Text] [Related]
18. [Long-term health insurance payments for depression in Germany - a secondary analysis of routine data].
Stamm K; Reinhard I; Salize HJ
Neuropsychiatr; 2010; 24(2):99-107. PubMed ID: 20605005
[TBL] [Abstract][Full Text] [Related]
19. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
20. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
Goldman DP; Joyce GF; Karaca-Mandic P
Am J Manag Care; 2006 Jan; 12(1):21-8. PubMed ID: 16402885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
